Monday, August 22, 2016

BRIEF-Lilly and Astrazeneca receive FDA fast track designation for AZD3293

* Lilly and Astrazeneca receive FDA fast track designation

for AZD3293, an investigational treatment for early Alzheimer's

disease

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)